BioTech & Lifescience

Life sciences and biotechnologies are fascinating, as scientific and medical breakthroughs can dramatically improve our quality of life. Supporting sophisticated technologies is both exciting and fulfilling.

We strive to support our clients in the life science and biotech industry on their mission to make the world a better place. In doing so, we give our very best to provide pragmatic solutions to complex challenges, always focusing on what really matters for our clients.

Over the years, we have developed a dedicated focus on the life science and biotech sector. Our clients include globally active pharma and biotech companies, research organizations, innovative technology start-ups and life science investors. Building upon the profound expertise and network which we have gained through our involvement in some of the most prominent biotech transactions in Europe, we advise our clients in the industry on all types of commercial and corporate transactions involving sophisticated technologies.

We assist on spin-off transactions involving universities and research institutes, partnerships, strategic collaborations and joint ventures. Further, we advise our clients on all commercial transactions spanning the product-life cycle in the life science sector, including R&D-related agreements, material transfer agreements, supply and distribution agreements, license agreements (including patent and technology licenses) and asset purchase transactions. In addition, we handle all types of fundraising, investments and M&A transactions in the life science and biotech industry.

Get in touch with us

Stephan Strass

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 15
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 8
            [filter] => raw
        )

)

Partner / Venture Capital & Start Ups, Corporate Law & Transactions, BioTech & Lifescience

Roman Rericha

Array
(
    [0] => WP_Term Object
        (
            [term_id] => 5
            [name] => Attorney at Law
            [slug] => attorney-at-law
            [term_group] => 0
            [term_taxonomy_id] => 5
            [taxonomy] => category
            [description] => 
            [parent] => 0
            [count] => 15
            [filter] => raw
        )

    [1] => WP_Term Object
        (
            [term_id] => 4
            [name] => Partner
            [slug] => partner
            [term_group] => 0
            [term_taxonomy_id] => 4
            [taxonomy] => category
            [description] => Partner
            [parent] => 0
            [count] => 8
            [filter] => raw
        )

)

Partner / Fund Formation, Venture Capital & Start Ups, Corporate Law & Transactions

Latest insights into
BioTech & Lifescience

BRANDL TALOS advises lead investor on EUR 18m Series A financing round of Ribbon Biolabs

Press release • Venture Capital & Start Ups from Roman Rericha, Stephan Strass

Ribbon Biolabs GmbH, a DNA synthesis company, has completed a EUR 18m Series A financing round led by Hadean Ventures with participation from, amongst others, Lansdowne Partners, Helicase Venture and existing investors IST cube and tecnet equity. A BRANDL TALOS-deal team led by Roman Rericha and Stephan Strass advised the lead investor, Hadean Ventures, on this financing round.

BRANDL TALOS advises AC Immune on the Acquisition of Parkinson's Disease Vaccine Candidate

• Corporate Law & Transactions from Roman Rericha, Stephan Strass, Raphael Toman, Alexander Stücklberger

Alongside Bär & Karrer, BRANDL TALOS advises AC Immune on the Strategic Acquisition of Industry-leading Parkinson's Disease Vaccine Candidate and Equity Investment

BRANDL TALOS advised shareholders of Allcyte on sale to Exscientia

Press release • Corporate Law & Transactions from Roman Rericha, Stephan Strass

Exscientia, a leading clinical stage pharmatech company, has entered into a binding agreement to acquire Allcyte, a leader in artificial intelligence (AI) based precision medicine. The transaction is subject to customary regulatory approvals.

Supporting new technologies